Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | FAP | Q12884 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13200730 | 0.85 | DPP4 (0.74) | DPP4CHRM1 | |
| SCHEMBL13200705 | 0.81 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL15683116 | 0.80 | DPP4 (0.66) | DPP4FAPKCNH2 | |
| SCHEMBL14554395 | 0.80 | DPP4 (1.00) | DPP4FAPKCNH2DPP8DPP9 | |
| SCHEMBL13200710 | 0.80 | DPP4 (0.66) | DPP4CHRM1 | |
| SCHEMBL14554318 | 0.79 | DPP4 (0.78) | DPP4FAPKCNH2DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL2967451 | 0.78 | DPP4 (0.64) | DPP4CHRM1 | |
| SCHEMBL14554368 | 0.78 | DPP4 (1.00) | DPP4FAPKCNH2DPP8DPP9 | |
| SCHEMBL3970996 | 0.77 | DPP4 (0.63) | DPP4FAPCHRM1DPP8DPP9 | |
| SCHEMBL14554320 | 0.77 | DPP4 (1.00) | DPP4FAPKCNH2DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051329-B2 | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051329-B2 | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140113920-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113920-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013006526-A2 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113920-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 22/4885KCNH2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.